Blog Archives

In the Headlines: Use Less Medicine

By Jessica Wapner
Posted: December 19, 2011

Category: Cancer Screening, Diagnostic testing, Medical Evidence | Tagged breast cancer, mammograms, overdiagnosis, prostate cancer, PSA, screening recommendations, U.S. Preventive Services Task Force | Leave a comment

The Person Behind the Prescriptions

By Jessica Wapner
Posted: November 23, 2011

Category: cancer | Tagged breast cancer, cancer, prescription drugs, side effects | Leave a comment

The Big Shortage—Where Have All the Drugs Gone?

By Jessica Wapner
Posted: October 19, 2011

Category: Drug Shortage | Tagged breast cancer, Dana-Farber Cancer Institute, daunorubicin, Doxil, doxorubicin, drug shortage, generic drugs, gray market, idarubicin, leukemia, Seattle Cancer Care Alliance, The Why Files | 2 Comments

The Many Reasons Why Personalized Medicine Is So Tricky

By Jessica Wapner
Posted: October 12, 2011

Category: cancer | Tagged BOLERO-2, breast cancer, cancer, European Multidisciplinary Cancer Congress, everolimus, gene sequencing, Gordon Mills, hormone therapy, M. D. Anderson Cancer Center, mTOR inhibitors, personalized medicine, targeted therapy | Leave a comment

Let the Death Panel Accusations Fly!

By Jessica Wapner
Posted: June 30, 2011

Category: Clinical Trials, Drug Development, ethics | Tagged Avastin, bevacizumab, breast cancer, drug approvals, drug development, FDA, Genentech, insurance coverage, National Comprehensive Cancer Network, ODAC | Leave a comment

The Avastin Saga

By Jessica Wapner
Posted: February 1, 2011

Category: cancer, drug cost, ethics | Tagged Avastin, breast cancer, cost:benefit ratio, FDA, insurance, Medicaid, medicare, NCCN, overall survival, progression-free survival | 8 Comments